Eveia's Technologies

• Technologies are fully functional and ready for development and commercialization
• Management team has relevant diagnostics company leadership experience, regulatory successes, and multiple high return exits
• Patents pending, exclusive ownership by Eveia and freedom to operate

Rapid Test Technology for Point-of-Care Diagnostics and Home Tests

The company's first products are single-use hand held devices for use in the home, the clinic or around the world to monitor blood disorders including anemia and coagulation.

EVEIA Homogeneous Immunoassay Technology

The EVEIA platform (Enhanced Velocity Electrophoretic ImmunoAssay) is an instrument based immunoassay  that improves the sensitivity, background, throughput, and batch requirements of ELISA detection systems currently at the heart of clinical immunoassay instruments. The technology allows a new generation of tests including cancer detection.